

# ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS



PHM062C  
March 2016

Ufuk Ezer  
*Project Analyst*

ISBN: 1-62296-266-4



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	3
SCOPE OF THE STUDY	3
INFORMATION SOURCES	3
METHODOLOGY	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	11
<i>SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	11
CHAPTER 3 OVERVIEW	13
ALZHEIMER'S DISEASE: DEFINITION AND MARKET STRUCTURE	13
<i>FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S., 2015-2030 (MILLIONS/\$ BILLIONS)</i>	14
ALZHEIMER'S DISEASE PATHOPHYSIOLOGY	15
AD AND AMYLOID CASCADE	16
AD AND TAUOPATHY	18
AD AND NEUROTRANSMITTER SYSTEMS	18
ALZHEIMER'S DISEASE ETIOLOGY	19
GENETIC FACTORS	19
Early-Onset Familial AD	19
Late-Onset Sporadic AD	20
NON-GENETIC FACTORS	20
ALZHEIMER'S DISEASE EPIDEMIOLOGY	20
AGE OF ONSET	20
INCIDENCE, PREVALENCE AND MORTALITY	21
Incidence of AD	21
Prevalence of AD	21
<i>TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%)</i>	21
<i>FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND REGION (%)</i>	21
<i>TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)</i>	22
<i>FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)</i>	22
Mortality in AD	23
STAGES AND SEVERITY OF AD	23
Stage 1: Asymptomatic AD	23
Stage 2: Very mild AD	23

<b>TOPIC</b>	<b>PAGE NO.</b>
Stage 3: Mild AD	23
Stage 4: Moderate AD	24
Stage 5: Moderately severe AD	24
Stage 6: Severe decline	24
Stage 7: Very severe AD	24
COMORBIDITIES	25
<i>TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S</i>	26
DIAGNOSIS AND TREATMENT OF ALZHEIMER'S	26
DIAGNOSIS OF ALZHEIMER'S	26
Cognitive Status Testing	27
ADAS-Cog	28
Computerized Screening Tests	28
<i>TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE IMPAIRMENT</i>	29
Genetic Testing	29
Brain Imaging	29
<i>TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S CONTEXT</i>	30
Lumbar Puncture	30
PHARMACEUTICAL TREATMENT OF AD	30
CHAPTER 4 REGULATORY LANDSCAPE	33
U.S. FOOD AND DRUG ADMINISTRATION	33
<i>TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA</i>	35
EUROPEAN MEDICINES AGENCY	35
CHAPTER 5 GLOBAL MARKETS	38
INTRODUCTION	38
MARKET DYNAMICS	38
TOP PLAYERS IN THE GLOBAL MARKET FOR AD THERAPEUTICS	39
<i>TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)</i>	40
<i>FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)</i>	40
GLOBAL MARKET FOR AD THERAPEUTICS AND DIAGNOSTICS	41
MARKET BY REGION	41
<i>FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2015 (%)</i>	41
<i>TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	43
<i>FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	43
MARKET BY APPLICATION SEGMENT	43
<i>TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	44
<i>FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, 2014-2020 (\$ MILLIONS)</i>	44
Global Market for AD Therapeutics	44
Global Market for AD Therapeutics by Region	45

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	46
<i>FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	46
Global Market for Branded/Generic AD Therapeutics	47
<i>TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	48
<i>FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)</i>	48
Global Market for AD Therapeutics by Mechanism of Action	49
<i>TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)</i>	50
<i>FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)</i>	50
Global Market for AChEIs	51
<i>TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)</i>	52
<i>FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	52
<i>TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	53
<i>FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, 2014-2020 (\$ MILLIONS)</i>	53
Global Market for NMDA Drugs	54
<i>TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	54
<i>FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)</i>	54
<i>TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	55
<i>FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 (\$ MILLIONS)</i>	55
Global Market for Other AD Therapeutics	56
<i>TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	57
<i>FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	57
Global Market for AD Therapeutics by AD Stage	57
<i>TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)</i>	59
<i>FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)</i>	59
Global Market for AD Diagnostics	60
Global AD Diagnostics Market by Region	60
<i>TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	61
<i>FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)</i>	61
Global AD Diagnostics Market by Molecular Target	62
<i>TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)</i>	63

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)</i>	63
CHAPTER 6 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS	65
NORTH AMERICAN MARKET	65
<i>TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	65
<i>FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)</i>	65
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY COUNTRY	66
<i>TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	66
<i>FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	67
NORTH AMERICAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS	67
<i>TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	68
<i>FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)</i>	68
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION	68
<i>TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)</i>	69
<i>FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)</i>	69
North American Market for AChEIs	70
<i>TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)</i>	70
<i>FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	70
<i>TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	71
<i>FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS MARKET BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	71
North American Market for NMDA Drugs	72
<i>TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	72
<i>FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)</i>	73
<i>TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	73
<i>FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	73
North American Market for Other AD Therapeutics	74
<i>TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	75
<i>FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	75
NORTH AMERICAN MARKET FOR AD THERAPEUTICS BY AD STAGE	75
<i>TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)</i>	76

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE 2014-2020 (\$ MILLIONS)</i>	76
<i>NORTH AMERICAN MARKET FOR AD DIAGNOSTICS BY MOLECULAR TARGET</i>	77
<i>TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)</i>	78
<i>FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)</i>	78
<b>CHAPTER 7 EUROPEAN MARKETS FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS</b>	80
<b>EUROPEAN MARKETS</b>	80
<i>TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	80
<i>FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)</i>	80
<b>EUROPEAN MARKET FOR AD THERAPEUTICS BY COUNTRY</b>	81
<i>TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	82
<i>FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	82
<b>EUROPEAN MARKET FOR BRANDED/GENERIC AD THERAPEUTICS</b>	82
<i>TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	83
<i>FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)</i>	83
<b>EUROPEAN MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION</b>	84
<i>TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)</i>	86
<i>FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)</i>	86
<b>European Market for AChEIs</b>	86
<i>TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)</i>	87
<i>FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	87
<i>TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	88
<i>FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	88
<b>European Market for NMDA Drugs</b>	88
<i>TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	89
<i>FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)</i>	89
<i>TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	90
<i>FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	90
<b>European Markets for Other AD Therapeutics</b>	91
<i>TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	91

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	91
EUROPEAN MARKET FOR AD THERAPEUTICS BY AD STAGE	92
<i>TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)</i>	93
<i>FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)</i>	93
EUROPEAN MARKET FOR AD DIAGNOSTICS	93
<i>TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)</i>	94
<i>FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)</i>	95
CHAPTER 8 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS	97
ASIA-PACIFIC MARKET	97
<i>TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	97
<i>FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)</i>	97
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY REGION	98
<i>TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	99
<i>FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	99
ASIA-PACIFIC MARKET FOR BRANDED/GENERIC AD THERAPEUTICS	100
<i>TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	100
<i>FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)</i>	100
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY MECHANISM OF ACTION	101
<i>TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)</i>	102
<i>FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)</i>	102
Asia-Pacific's Market for AChEIs	102
<i>TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)</i>	103
<i>FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	103
<i>TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	104
<i>FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	104
Asia-Pacific Market for NMDA Drugs	104
<i>TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	105
<i>FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)</i>	105
<i>TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)</i>	106

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)</i>	106
ASIA-PACIFIC MARKET FOR AD THERAPEUTICS BY AD STAGE	106
<i>TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)</i>	107
<i>FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)</i>	107
ASIA-PACIFIC MARKET FOR AD DIAGNOSTICS	108
<i>TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)</i>	109
<i>FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)</i>	109
CHAPTER 9 PIPELINE ANALYSIS	111
AD PIPELINE LANDSCAPE	111
AD PIPELINE: CLINICAL STAGE	112
<i>FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE (NUMBER OF DRUGS)</i>	112
AD PIPELINE: TREATMENT FOCUS	112
<i>FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)</i>	113
AD PIPELINE BY DISEASE STAGE	114
<i>FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF DRUGS)</i>	114
AD PIPELINE: MECHANISM OF ACTION	115
<i>FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)</i>	116
<i>TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION</i>	116
MAJOR AB-BASED THERAPIES IN CLINICAL TRIALS	117
BIIB037/ADUCANUMAB	117
Mode of Action	117
Clinical Trial Snapshot	117
Phase I Trials	117
Phase III Trials	118
ENGAGE and EMERGE	118
Safety	118
Efficacy	118
Administration	118
SOLANEZUMAB/LY2062430	119
Mode of Action	119
Clinical Trial Snapshot	119
Phase I Trial	119
Phase II Trials	119
Phase III Trials	120
EXPEDITION 1 and 2	120
Safety	121
Efficacy	121
Administration	121



<b>TOPIC</b>	<b>PAGE NO.</b>
RG1450/GANTENERUMAB	121
Mode of Action	121
Clinical Trial Snapshot	121
Phase I Trials	121
Phase II/III Trials	122
Efficacy	122
Administration	122
RG7412/CRENEZUMAB	122
Mode of Action	123
Clinical Trial Snapshot	123
Phase I Trials	123
Phase II Trials	123
Safety	124
Efficacy	124
Administration	124
MK-8931/VERUBECESTAT	124
Mode of Action	124
Clinical Trial Snapshot	125
Phase I Trials	125
Phase II Trials	125
Phase III Trials	125
Safety	126
Efficacy	126
Administration	126
Benchmarking	126
CAD106	127
Mode of Action	127
Clinical Trial Snapshot	127
Phase I Trial	127
Phase II Trials	127
Phase III Trials	128
Safety	128
Efficacy	128
Administration	128
MAJOR TAU-BASED THERAPIES IN CLINICAL TRIALS	128
LMTX	128
Mode of Action	129
Clinical Trial Snapshot	129
Phase I and II Trials	129
Phase III Trials	129
Safety	130
Efficacy	130
Administration	130
CHAPTER 10 COMPANION DIAGNOSTICS	132
INTRODUCTION	132
<i>FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS (%)</i>	132

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET</i>	132
COMPANION IMAGING DIAGNOSTICS FOR AD	135
<i>FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%)</i>	135
<i>FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER OF TRIALS)</i>	136
CIDX TECHNOLOGIES FOR AMYLOID VISUALIZATION	137
Market	137
<i>TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS</i>	138
Pipeline	138
NAV-4694	138
Comparative Analysis of AB Tracer Technologies	139
Diagnostic Efficacy	139
Safety	139
Diagnostic Utility	139
CIDX TECHNOLOGIES FOR TAU-NFT VISUALIZATION	140
AV-1451	140
THK-5351	140
RO6958948	141
Comparative Analysis of Tau Tracers in Development	141
Diagnostic Efficacy	141
Safety	142
Diagnostic Utility	142
CIDX TECHNOLOGIES: AB VERSUS TAU IMAGING TECHNOLOGIES	142
CONCLUDING REMARKS	143
CHAPTER 11 COMPANY PROFILES	145
AB SCIENCE	145
ABBVIE INC.	145
AC IMMUNE SA	145
ALLERGAN PLC	146
AFFIRIS AG	146
AMARANTUS BIOSCIENCE HOLDINGS	146
ANAVEX LIFE SCIENCES	147
ASTRAZENECA	147
AVID RADIOPHARMACEUTICALS	148
AXON NEUROSCIENCE	148
AXOVANT SCIENCES	148
BIOGEN	149
BOEHRINGER INGELHEIM	149
DAIICHI SANKYO CO	149
DIAGENIC	150
EISAI	150
ELI LILLY	150
F. HOFFMANN LA ROCHE AG	151
GE HEALTHCARE	151
H. LUNDBECK A/S	151
JANSSEN PHARMACEUTICALS	152
MERCK & CO	152

<b>TOPIC</b>	<b>PAGE NO.</b>
NAVIDEA BIOPHARMACEUTICALS	152
NEUROTRAX CORP.	153
NOVARTIS PHARMA SERVICES AG	153
ONO PHARMACEUTICAL CO.	153
OTSUKA PHARMACEUTICALS	154
PFIZER INC	154
PIRAMAL IMAGING GMBH	154
TAURX THERAPEUTICS	155

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	11
TABLE 1 PREVALENCE RATES OF ALZHEIMER'S BY REGION, 2014 (%)	21
TABLE 2 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)	22
TABLE 3 PHARMACOLOGICAL TREATMENT OF BPSD OF ALZHEIMER'S	26
TABLE 4 COMPUTERIZED SCREENING TESTS USED IN DETECTING COGNITIVE IMPAIRMENT	29
TABLE 5 BRAIN IMAGING TECHNOLOGIES AND APPLICATION IN THE ALZHEIMER'S CONTEXT	30
TABLE 6 DIAGNOSTIC IMAGING TRACERS APPROVED BY THE FDA	35
TABLE 7 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)	40
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	43
TABLE 9 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	44
TABLE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	46
TABLE 11 GLOBAL MARKET FOR GENERIC/BRANDED ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	48
TABLE 12 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)	50
TABLE 13 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)	52
TABLE 14 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, THROUGH 2020 (\$ MILLIONS)	53
TABLE 15 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)	54
TABLE 16 GLOBAL MARKET FOR NMDA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	55
TABLE 17 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	57
TABLE 18 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)	59
TABLE 19 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	61
TABLE 20 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)	63
TABLE 21 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)	65
TABLE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	66
TABLE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	68
TABLE 24 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)	69
TABLE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)	70
TABLE 26 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	71

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 27 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)	72
TABLE 28 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	73
TABLE 29 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	75
TABLE 30 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)	76
TABLE 31 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)	78
TABLE 32 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)	80
TABLE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	82
TABLE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	83
TABLE 35 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)	86
TABLE 36 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)	87
TABLE 37 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	88
TABLE 38 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 39 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	90
TABLE 40 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	91
TABLE 41 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)	93
TABLE 42 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)	94
TABLE 43 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, THROUGH 2020 (\$ MILLIONS)	97
TABLE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	99
TABLE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	100
TABLE 46 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLIN-ESTERASE INHIBITORS, THROUGH 2020 (\$ MILLIONS)	103
TABLE 48 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	104
TABLE 49 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 50 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	106
TABLE 51 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, THROUGH 2020 (\$ MILLIONS)	107
TABLE 52 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, THROUGH 2020 (\$ MILLIONS)	109

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 53 GLOBAL ALZHEIMER'S DRUGS IN THE PIPELINE BY MECHANISM OF ACTION	116
TABLE 54 CIDX-DRUG PAIRS IN CLINICAL TRIALS	138

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)	11
FIGURE 1 CHANGE IN ALZHEIMER'S POPULATION AND COST OF CARE IN THE U.S., 2015-2030 (MILLIONS/\$ BILLIONS)	14
FIGURE 2 GLOBAL PREVALENCE RATES OF ALZHEIMER'S BY AGE GROUP AND REGION (%)	21
FIGURE 3 GLOBAL ALZHEIMER'S POPULATION BY AGE GROUP AND REGION, 2014 (MILLIONS)	22
FIGURE 4 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ALZHEIMER'S THERAPEUTICS, 2020 (%)	40
FIGURE 5 GLOBAL MARKET SHARES OF ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2015 (%)	41
FIGURE 6 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)	43
FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION, 2014-2020 (\$ MILLIONS)	44
FIGURE 8 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)	46
FIGURE 9 GLOBAL MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)	48
FIGURE 10 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)	50
FIGURE 11 GLOBAL MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)	52
FIGURE 12 GLOBAL MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY REGION, 2014-2020 (\$ MILLIONS)	53
FIGURE 13 GLOBAL MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)	54
FIGURE 14 GLOBAL MARKET FOR NMDA DRUGS BY REGION, 2014-2020 (\$ MILLIONS)	55
FIGURE 15 GLOBAL MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY REGION, 2014-2020 (\$ MILLIONS)	57
FIGURE 16 GLOBAL MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)	59
FIGURE 17 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY REGION, 2014-2020 (\$ MILLIONS)	61
FIGURE 18 GLOBAL MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)	63
FIGURE 19 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)	65
FIGURE 20 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)	67
FIGURE 21 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)	68
FIGURE 22 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)	69
FIGURE 23 NORTH AMERICAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)	70
FIGURE 24 NORTH AMERICAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS MARKET BY COUNTRY, 2014-2020 (\$ MILLIONS)	71
FIGURE 25 NORTH AMERICAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)	73

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 26 NORTH AMERICAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)	73
FIGURE 27 NORTH AMERICAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)	75
FIGURE 28 NORTH AMERICAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE 2014-2020 (\$ MILLIONS)	76
FIGURE 29 NORTH AMERICAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)	78
FIGURE 30 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)	80
FIGURE 31 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, 2014-2020 (\$ MILLIONS)	82
FIGURE 32 EUROPEAN MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)	83
FIGURE 33 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)	86
FIGURE 34 EUROPEAN MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)	87
FIGURE 35 EUROPEAN MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 (\$ MILLIONS)	88
FIGURE 36 EUROPEAN MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)	89
FIGURE 37 EUROPEAN MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)	90
FIGURE 38 EUROPEAN MARKET FOR OTHER ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	91
FIGURE 39 EUROPEAN MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)	93
FIGURE 40 EUROPEAN MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)	95
FIGURE 41 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS AND DIAGNOSTICS BY APPLICATION SEGMENT, 2014-2020 (\$ MILLIONS)	97
FIGURE 42 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY COUNTRY, THROUGH 2020 (\$ MILLIONS)	99
FIGURE 43 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ALZHEIMER'S THERAPEUTICS, 2014-2020 (\$ MILLIONS)	100
FIGURE 44 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY MECHANISM OF ACTION, 2014-2020 (\$ MILLIONS)	102
FIGURE 45 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC ACETYLCHOLINESTERASE INHIBITORS, 2014-2020 (\$ MILLIONS)	103
FIGURE 46 ASIA-PACIFIC MARKET FOR ACETYLCHOLINESTERASE INHIBITORS BY COUNTRY, 2014-2020 (\$ MILLIONS)	104
FIGURE 47 ASIA-PACIFIC MARKET FOR BRANDED/GENERIC NMDA DRUGS, 2014-2020 (\$ MILLIONS)	105
FIGURE 48 ASIA-PACIFIC MARKET FOR NMDA DRUGS BY COUNTRY, 2014-2020 (\$ MILLIONS)	106
FIGURE 49 ASIA-PACIFIC MARKET FOR ALZHEIMER'S THERAPEUTICS BY DISEASE STAGE, 2014-2020 (\$ MILLIONS)	107
FIGURE 50 ASIA-PACIFIC MARKET FOR ALZHEIMER'S DIAGNOSTICS BY MOLECULAR TARGET, 2014-2020 (\$ MILLIONS)	109
FIGURE 51 ALZHEIMER'S DRUGS IN THE PIPELINE BY DEVELOPMENT STAGE (NUMBER OF DRUGS)	112



<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 52 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)	113
FIGURE 53 LATE PHASE II/III ALZHEIMER'S DRUGS BY DISEASE STAGE (NUMBER OF DRUGS)	114
FIGURE 54 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)	116
FIGURE 55 FDA-APPROVED CDX TECHNOLOGIES BY INDICATED THERAPEUTIC CLASS (%)	132
FIGURE 56 FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET	132
FIGURE 57 ONGOING AB AND TAU PET IMAGING CLINICAL TRIALS (%)	135
FIGURE 58 AB AND TAU PET IMAGING TRIALS BY CLINICAL TRIAL PHASE (NUMBER OF TRIALS)	136